Clearstead Advisors
MBOT icon

Clearstead Advisors’s Microbot Medical MBOT Stock Holding History

Clearstead Advisors’s Portfolio MBOT Stock Details MBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.68K Buy
860
+585
+213% +$1.19K ﹤0.01% 2536
2026
Q1 		$663 Hold
275
– – ﹤0.01% 2093
2025
Q4 		$550 Buy
+275
New +$651 ﹤0.01% 2300

Other funds holding MBOT

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DnB Asset Management
DnB Asset Management Oslo, Norway $35.7B AUM 27.58% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Clearstead Advisors's MBOT Position: Q2 2026 in Review

Clearstead Advisors increased its Microbot Medical (MBOT) stake by 213% in Q2 2026, buying an estimated $1.19K and bringing the position to 860 shares worth $1.68K. The position accounts for ﹤0.01% of the portfolio, ranked #2536.

Clearstead Advisors first reported a position in MBOT in Q4 2025 and has held it in 3 quarters since. 71 funds tracked by Wall St. Rank hold MBOT as of Q2 2026.

  • Clearstead Advisors held 860 shares of Microbot Medical worth $1.68K as of Q2 2026.
  • Clearstead Advisors bought 585 Microbot Medical shares in Q2 2026, an estimated $1.19K.
  • Microbot Medical made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2536 holding.
  • Clearstead Advisors first reported a position in Microbot Medical in Q4 2025 and has held it in 3 quarters since.
  • 71 funds tracked by Wall St. Rank held Microbot Medical as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.